Treatment of typical (enteropathic) hemolytic uremic syndrome

Seminars in Thrombosis and Hemostasis

Volumn 36, Issue 6, 2010, Pages 594-610

  Bitzan, Martin ^a   Schaefer, Franz ^b   Reymond, Didier ^c  

^a MONTREAL CHILDREN S HOSPITAL   (Canada)

^b UNIVERSITY OF HEIDELBERG   (Germany)

^c Thallion Pharmaceuticals Inc   (Canada)

Author keywords

anti Shiga toxin antibody; children; dialysis; Hemolytic uremic syndrome; Shiga toxin

Indexed keywords

ANTIBIOTIC AGENT; AZITHROMYCIN; CERAMIDE DERIVATIVE; CIPROFLOXACIN; COTRIMOXAZOLE; DIPYRIDAMOLE; FOSFOMYCIN; FRESH FROZEN PLASMA; FUROSEMIDE; GLUCOCORTICOID; HEPARIN; LOOP DIURETIC AGENT; MONOCLONAL ANTIBODY; MORPHINE; NONSTEROID ANTIINFLAMMATORY AGENT; PARACETAMOL; PLACEBO; PREDNISONE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RECOMBINANT EXOTOXIN A; SHIGA TOXIN; SHIGATOXIN ANTIBODY; SODIUM CHLORIDE; STX BINDING GLOBOTRIAOSYL CERAMIDE DERIVATIVE; SYNSORB PK; TOXIN; TOXIN ANTIBODY; UNCLASSIFIED DRUG; UROKINASE;

ABDOMINAL PAIN; ABSENCE OF SIDE EFFECTS; BACTERIAL INFECTION; BLEEDING; BLOOD TRANSFUSION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; DIALYSIS; DIARRHEA; DRUG MEGADOSE; EXTRACORPOREAL CIRCULATION; GASTROINTESTINAL HEMORRHAGE; HEMODIALYSIS; HEMOLYTIC UREMIC SYNDROME; HEMORRHAGIC COLITIS; HUMAN; INFECTION CONTROL; NONHUMAN; NUTRITIONAL SUPPORT; PLASMAPHERESIS; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RENAL REPLACEMENT THERAPY; REVIEW; SHIGA TOXIN PRODUCING ESCHERICHIA COLI; SOCIAL ISOLATION; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; CHILD; ESCHERICHIA COLI INFECTIONS; HEMOLYTIC-UREMIC SYNDROME; HOST-PATHOGEN INTERACTIONS; HUMANS; RENAL DIALYSIS; SHIGA TOXIN; SHIGA-TOXIGENIC ESCHERICHIA COLI; TREATMENT OUTCOME;

EID: 77957587756     PISSN: 00946176     EISSN: 10989064     Source Type: Journal    
DOI: 10.1055/s-0030-1262881     Document Type: Review

References (151)

1. Karmali M A., Petric M, Lim C, Fleming P C., Arbus G S., Lior H. The association between idiopathic hemolytic uremic syndrome and infection by verotoxin-producing Escherichia coli. J Infect Dis 1985 151 (5) 775-782
2. Tarr P I., Gordon C A., Chandler W L. Shiga-toxin-producing Escherichia coli and haemolytic uraemic syndrome. Lancet 2005 365 (9464) 1073-1086
3. Loirat C, Noris M, Frémeaux-Bacchi V. Complement and the atypical hemolytic uremic syndrome in children. Pediatr Nephrol 2008 23 (11) 1957-1972
4. Skerka C, Józsi M, Zipfel P F., Dragon-Durey M A., Frémeaux-Bacchi V. Autoantibodies in haemolytic uraemic syndrome (HUS). Thromb Haemost 2009 101 (2) 227-232
5. Goldwater P N. Treatment and prevention of enterohemorrhagic Escherichia coli infection and hemolytic uremic syndrome. Expert Rev Anti Infect Ther 2007 5 (4) 653-663
6. Konowalchuk J, Speirs J I., Stavric S. Vero response to a cytotoxin of Escherichia coli. Infect Immun 1977 18 (3) 775-779
7. Karmali M A., Steele B T., Petric M, Lim C. Sporadic cases of haemolytic-uraemic syndrome associated with faecal cytotoxin and cytotoxin-producing Escherichia coli in stools. Lancet 1983 1 (8325) 619-620
8. Bitzan M, Poole R, Mehran M et al. Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother 2009 53 (7) 3081-3087
9. Butler T, Islam M R., Azad M A., Jones P K. Risk factors for development of hemolytic uremic syndrome during shigellosis. J Pediatr 1987 110 (6) 894-897
10. Bhimma R, Rollins N C., Coovadia H M., Adhikari M. Post-dysenteric hemolytic uremic syndrome in children during an epidemic of Shigella dysentery in Kwazulu/Natal. Pediatr Nephrol 1997 11 (5) 560-564
11. Mark Taylor C. Enterohaemorrhagic Escherichia coli and Shigella dysenteriae type 1-induced haemolytic uraemic syndrome. Pediatr Nephrol 2008 23 (9) 1425-1431
12. O'Brien A D., LaVeck G D., Thompson M R., Formal S B. Production of Shigella dysenteriae type 1-like cytotoxin by Escherichia coli. J Infect Dis 1982 146 (6) 763-769
13. Houdouin V, Doit C, Mariani P et al. A pediatric cluster of Shigella dysenteriae serotype 1 diarrhea with hemolytic uremic syndrome in 2 families from France. Clin Infect Dis 2004 38 (9) e96-e99
14. Tschäpe H, Prager R, Streckel W, Fruth A, Tietze E, Böhme G. Verotoxinogenic Citrobacter freundii associated with severe gastroenteritis and cases of haemolytic uraemic syndrome in a nursery school: green butter as the infection source. Epidemiol Infect 1995 114 (3) 441-450
15. Wickham M E., Lupp C, Mascarenhas M et al. Bacterial genetic determinants of non-O157 STEC outbreaks and hemolytic-uremic syndrome after infection. J Infect Dis 2006 194 (6) 819-827
16. Lee S Y., Lee M S., Cherla R P., Tesh V L. Shiga toxin 1 induces apoptosis through the endoplasmic reticulum stress response in human monocytic cells. Cell Microbiol 2008 10 (3) 770-780
17. Siegler R L., Pysher T J., Tesh V L., Taylor F B. Jr. Response to single and divided doses of Shiga toxin-1 in a primate model of hemolytic uremic syndrome. J Am Soc Nephrol 2001 12 (7) 1458-1467
18. Hertzke D M., Cowan L A., Schoning P, Fenwick B W. Glomerular ultrastructural lesions of idiopathic cutaneous and renal glomerular vasculopathy of greyhounds. Vet Pathol 1995 32 (5) 451-459
19. Sauter K A., Melton-Celsa A R., Larkin K, Troxell M L., O'Brien A D., Magun B E. Mouse model of hemolytic-uremic syndrome caused by endotoxin-free Shiga toxin 2 (Stx2) and protection from lethal outcome by anti-Stx2 antibody. Infect Immun 2008 76 (10) 4469-4478
20. Richardson S E., Rotman T A., Jay V et al. Experimental verocytotoxemia in rabbits. Infect Immun 1992 60 (10) 4154-4167
21. Sheoran A S., Chapman-Bonofiglio S, Harvey B R. et al. Human antibody against shiga toxin 2 administered to piglets after the onset of diarrhea due to Escherichia coli O157:H7 prevents fatal systemic complications. Infect Immun 2005 73 (8) 4607-4613
22. Aldick T, Bielaszewska M, Zhang W et al. Hemolysin from Shiga toxin-negative Escherichia coli O26 strains injures microvascular endothelium. Microbes Infect 2007 9 (3) 282-290
23. Wang H, Paton J C., Paton A W. Pathologic changes in mice induced by subtilase cytotoxin, a potent new Escherichia coli AB5 toxin that targets the endoplasmic reticulum. J Infect Dis 2007 196 (7) 1093-1101
24. Löfling J C., Paton A W., Varki N M., Paton J C., Varki A. A dietary non-human sialic acid may facilitate hemolytic-uremic syndrome. Kidney Int 2009 76 (2) 140-144
25. Ochoa T J., Cleary T G. Epidemiology and spectrum of disease of Escherichia coli O157. Curr Opin Infect Dis 2003 16 (3) 259-263
26. Rowe P C., Orrbine E, Lior H et al, Investigators of the Canadian Pediatric Kidney Disease Research Center. Risk of hemolytic uremic syndrome after sporadic Escherichia coli O157:H7 infection: results of a Canadian collaborative study. J Pediatr 1998 132 (5) 777-782
27. Klein E J., Stapp J R., Clausen C R. et al. Shiga toxin-producing Escherichia coli in children with diarrhea: a prospective point-of-care study. J Pediatr 2002 141 (2) 172-177
28. Mellmann A, Bielaszewska M, Köck R et al. Analysis of collection of hemolytic uremic syndrome-associated enterohemorrhagic Escherichia coli. Emerg Infect Dis 2008 14 (8) 1287-1290
29. Alpers K, Werber D, Frank C et al. Sorbitol-fermenting enterohaemorrhagic Escherichia coli O157:H- causes another outbreak of haemolytic uraemic syndrome in children. Epidemiol Infect 2009 137 (3) 389-395
30. Oakes R S., Siegler R L., McReynolds M A., Pysher T, Pavia A T. Predictors of fatality in postdiarrheal hemolytic uremic syndrome. Pediatrics 2006 117 (5) 1656-1662
31. Proulx F, Sockett P. Prospective surveillance of Canadian children with the haemolytic uraemic syndrome. Pediatr Nephrol 2005 20 (6) 786-790
32. Riley L W., Remis R S., Helgerson S D. et al. Hemorrhagic colitis associated with a rare Escherichia coli serotype. N Engl J Med 1983 308 (12) 681-685
33. Blanco J E., Blanco M, Alonso M P. et al. Serotypes, virulence genes, and intimin types of Shiga toxin (verotoxin)-producing Escherichia coli isolates from human patients: prevalence in Lugo, Spain, from 1992 through 1999. J Clin Microbiol 2004 42 (1) 311-319
34. Reiss G, Kunz P, Koin D, Keeffe E B. Escherichia coli O157:H7 infection in nursing homes: review of literature and report of recent outbreak. J Am Geriatr Soc 2006 54 (4) 680-684
35. Siegler R, Oakes R. Hemolytic uremic syndrome; pathogenesis, treatment, and outcome. Curr Opin Pediatr 2005 17 (2) 200-204
36. De Petris L, Gianviti A, Giordano U, Calzolari A, Tozzi A E., Rizzoni G. Blood pressure in the long-term follow-up of children with hemolytic uremic syndrome. Pediatr Nephrol 2004 19 (11) 1241-1244 (Pubitemid 39462425)
37. Cobeas C J., Alconcher L F., Spizzirri A P., Rahman R C. Long-term follow-up of Argentinean patients with hemolytic uremic syndrome who had not undergone dialysis. Pediatr Nephrol 2007 22 (9) 1343-1347
38. Garg A X., Clark W F., Salvadori M et al, Walkerton Health Study Investigators. Microalbuminuria three years after recovery from Escherichia coli O157 hemolytic uremic syndrome due to municipal water contamination. Kidney Int 2005 67 (4) 1476-1482
39. Pollock K G., Duncan E, Cowden J M. Emotional and behavioral changes in parents of children affected by hemolytic-uremic syndrome associated with verocytotoxin-producing Escherichia coli: a qualitative analysis. Psychosomatics 2009 50 (3) 263-269
40. Havelaar A H., Van Duynhoven Y T., Nauta M J. et al. Disease burden in The Netherlands due to infections with Shiga toxin-producing Escherichia coli O157. Epidemiol Infect 2004 132 (3) 467-484
41. Frenzen P D., Drake A, Angulo F J., Emerging Infections Program FoodNet Working Group. Economic cost of illness due to Escherichia coli O157 infections in the United States. J Food Prot 2005 68 (12) 2623-2630
42. Ake J A., Jelacic S, Ciol M A. et al. Relative nephroprotection during Escherichia coli O157:H7 infections: association with intravenous volume expansion. Pediatrics 2005 115 (6) e673-e680
43. Ahn C K., Holt N J., Tarr P I. Shiga-toxin producing Escherichia coli and the hemolytic uremic syndrome: what have we learned in the past 25 years? Adv Exp Med Biol 2009 634 1-17
44. Liu H C., Anday J K., House S D., Chang S L. Dual effects of morphine on permeability and apoptosis of vascular endothelial cells: morphine potentiates lipopolysaccharide-induced permeability and apoptosis of vascular endothelial cells. J Neuroimmunol 2004 146 (1-2) 13-21
45. Bell B P., Griffin P M., Lozano P, Christie D L., Kobayashi J M., Tarr P I. Predictors of hemolytic uremic syndrome in children during a large outbreak of Escherichia coli O157:H7 infections. Pediatrics 1997 100 (1) E12
46. Wong C S., Jelacic S, Habeeb R L., Watkins S L., Tarr P I. The risk of the hemolytic-uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 infections. N Engl J Med 2000 342 (26) 1930-1936
47. Araujo M, Welch W J. Cyclooxygenase 2 inhibition suppresses tubuloglomerular feedback: roles of thromboxane receptors and nitric oxide. Am J Physiol Renal Physiol 2009 296 (4) F790-F794
48. Buteau C, Proulx F, Chaibou M et al. Leukocytosis in children with Escherichia coli O157:H7 enteritis developing the hemolytic-uremic syndrome. Pediatr Infect Dis J 2000 19 (7) 642-647
49. Kawamura N, Yamazaki T, Tamai H. Risk factors for the development of Escherichia coli O157:H7 associated with hemolytic uremic syndrome. Pediatr Int 1999 41 (2) 218-222
50. Decaluwe H, Harrison L M., Mariscalco M M. et al. Procalcitonin in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome. Pediatr Res 2006 59 (4 Pt 1) 579-583
51. Rowe P C., Orrbine E, Lior H, Wells G A., McLaine P N. Diarrhoea in close contacts as a risk factor for childhood haemolytic uraemic syndrome. The CPKDRC co-investigators. Epidemiol Infect 1993 110 (1) 9-16
52. Tuttle J, Gomez T, Doyle M P. et al. Lessons from a large outbreak of Escherichia coli O157:H7 infections: insights into the infectious dose and method of widespread contamination of hamburger patties. Epidemiol Infect 1999 122 (2) 185-192
53. Cornick N A., Jelacic S, Ciol M A., Tarr P I. Escherichia coli O157:H7 infections: discordance between filterable fecal Shiga toxin and disease outcome. J Infect Dis 2002 186 (1) 57-63
54. Ahn C K., Klein E, Tarr P I. Isolation of patients acutely infected with Escherichia coli O157:H7: low-tech, highly effective prevention of hemolytic uremic syndrome. Clin Infect Dis 2008 46 (8) 1197-1199
55. Belongia E A., Osterholm M T., Soler J T., Ammend D A., Braun J E., MacDonald K L. Transmission of Escherichia coli O157:H7 infection in Minnesota child day-care facilities. JAMA 1993 269 (7) 883-888
56. Werber D, Mason B W., Evans M R., Salmon R L. Preventing household transmission of Shiga toxin-producing Escherichia coli O157 infection: promptly separating siblings might be the key. Clin Infect Dis 2008 46 (8) 1189-1196
57. Oakes R S., Kirkham J K., Kirkhamm J K., Nelson R D., Siegler R L. Duration of oliguria and anuria as predictors of chronic renal-related sequelae in post-diarrheal hemolytic uremic syndrome. Pediatr Nephrol 2008 23 (8) 1303-1308
58. Rousseau E, Blais N, O'Regan S. Decreased necessity for dialysis with loop diuretic therapy in hemolytic uremic syndrome. Clin Nephrol 1990 34 (1) 22-25
59. Ho K M., Sheridan D J. Meta-analysis of frusemide to prevent or treat acute renal failure. BMJ 2006 333 (7565) 420
60. Bagshaw S M., Bellomo R, Kellum J A. Oliguria, volume overload, and loop diuretics. Crit Care Med 2008 36 (4, Suppl) S172-S178
61. Pape L, Ahlenstiel T, Kreuzer M et al. Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome: a randomized prospective pilot trial. Pediatr Nephrol 2009 24 (5) 1061-1064
62. Proulx F, Turgeon J P., Delage G, Lafleur L, Chicoine L. Randomized, controlled trial of antibiotic therapy for Escherichia coli O157:H7 enteritis. J Pediatr 1992 121 (2) 299-303
63. Takeda T, Yoshina K-i, Uchida H, Ikeda N, Tanimura M. Early use of fosfomycin for Shiga toxin-producing Escherichia coli O157 infection reduces the risk of hemolytic-uremic syndrome In: Kaper JB, O'Brien AD Escherichia coli O157:H7 and Other Shiga Toxin-Producing E coli Strains. Washington, DC ASM Press 1998 385-387
64. Kurioka T, Yunou Y, Harada H, Kita E. Efficacy of antibiotic therapy for infection with Shiga-like toxin-producing Escherichia coli O157:H7 in mice with protein-calorie malnutrition. Eur J Clin Microbiol Infect Dis 1999 18 (8) 561-571
65. Shiomi M, Togawa M, Fujita K, Murata R. Effect of early oral fluoroquinolones in hemorrhagic colitis due to Escherichia coli O157:H7. Pediatr Int 1999 41 (2) 228-232
66. Mlbak K, Mead P S., Griffin P M. Antimicrobial therapy in patients with Escherichia coli O157:H7 infection. JAMA 2002 288 (8) 1014-1016
67. Johnson S, Taylor C M. What's new in haemolytic uraemic syndrome? Eur J Pediatr 2008 167 (9) 965-971
68. Orth D, Grif K, Zimmerhackl L B., Würzner R. Prevention and treatment of enterohemorrhagic Escherichia coli infections in humans. Expert Rev Anti Infect Ther 2008 6 (1) 101-108
69. Slutsker L, Ries A A., Maloney K, Wells J G., Greene K D., Griffin P M. A nationwide case-control study of Escherichia coli O157:H7 infection in the United States. J Infect Dis 1998 177 (4) 962-966
70. Walterspiel J N., Ashkenazi S, Morrow A L., Cleary T G. Effect of subinhibitory concentrations of antibiotics on extracellular Shiga-like toxin I. Infection 1992 20 (1) 25-29
71. Bitzan M, Müller-Wiefel D E., Schwarzkopf A, Karch H. The role of antibiotics in the management of verotoxin-associated hemolytic anemia syndromes [in German]. Immun Infekt 1992 20 (5) 168-172
72. Grif K, Dierich M P., Karch H, Allerberger F. Strain-specific differences in the amount of Shiga toxin released from enterohemorrhagic Escherichia coli O157 following exposure to subinhibitory concentrations of antimicrobial agents. Eur J Clin Microbiol Infect Dis 1998 17 (11) 761-766
73. Zhang X, McDaniel A D., Wolf L E., Keusch G T., Waldor M K., Acheson D W. Quinolone antibiotics induce Shiga toxin-encoding bacteriophages, toxin production, and death in mice. J Infect Dis 2000 181 (2) 664-670
74. Safdar N, Said A, Gangnon R E., Maki D G. Risk of hemolytic uremic syndrome after antibiotic treatment of Escherichia coli O157:H7 enteritis: a meta-analysis. JAMA 2002 288 (8) 996-1001 (Pubitemid 34920465)
75. Zhang Q, Donohue-Rolfe A, Krautz-Peterson G et al. Gnotobiotic piglet infection model for evaluating the safe use of antibiotics against Escherichia coli O157:H7 infection. J Infect Dis 2009 199 (4) 486-493
76. Benigni A, Boccardo P, Noris M, Remuzzi G, Siegler R L. Urinary excretion of platelet-activating factor in haemolytic uraemic syndrome. Lancet 1992 339 (8797) 835-836
77. Karpman D, Andreasson A, Thysell H, Kaplan B S., Svanborg C. Cytokines in childhood hemolytic uremic syndrome and thrombotic thrombocytopenic purpura. Pediatr Nephrol 1995 9 (6) 694-699
78. Inward C D., Varagunam M, Adu D, Milford D V., Taylor C M. Cytokines in haemolytic uraemic syndrome associated with verocytotoxin-producing Escherichia coli infection. Arch Dis Child 1997 77 (2) 145-147
79. Bitzan M M., Wang Y, Lin J, Marsden P A. Verotoxin and ricin have novel effects on preproendothelin-1 expression but fail to modify nitric oxide synthase (ecNOS) expression and NO production in vascular endothelium. J Clin Invest 1998 101 (2) 372-382
80. Westerholt S, Pieper A K., Griebel M, Volk H D., Hartung T, Oberhoffer R. Characterization of the cytokine immune response in children who have experienced an episode of typical hemolytic-uremic syndrome. Clin Diagn Lab Immunol 2003 10 (6) 1090-1095
81. Siegler R L., Pysher T J., Tesh V L., Noris M, Cassis P, Taylor F B. Jr. Reduced nitric oxide bioavailability in a baboon model of Shiga toxin mediated hemolytic uremic syndrome (HUS). Ren Fail 2005 27 (5) 635-641
82. Bombeli T, Karsan A, Tait J F., Harlan J M. Apoptotic vascular endothelial cells become procoagulant. Blood 1997 89 (7) 2429-2442
83. Nestoridi E, Kushak R I., Duguerre D, Grabowski E F., Ingelfinger J R. Up-regulation of tissue factor activity on human proximal tubular epithelial cells in response to Shiga toxin. Kidney Int 2005 67 (6) 2254-2266
84. Nestoridi E, Tsukurov O, Kushak R I., Ingelfinger J R., Grabowski E F. Shiga toxin enhances functional tissue factor on human glomerular endothelial cells: implications for the pathophysiology of hemolytic uremic syndrome. J Thromb Haemost 2005 3 (4) 752-762
85. Simoncini S, Njock M S., Robert S et al. TRAIL/Apo2L mediates the release of procoagulant endothelial microparticles induced by thrombin in vitro: a potential mechanism linking inflammation and coagulation. Circ Res 2009 104 (8) 943-951
86. Chandler W L., Jelacic S, Boster D R. et al. Prothrombotic coagulation abnormalities preceding the hemolytic-uremic syndrome. N Engl J Med 2002 346 (1) 23-32
87. Richardson S E., Karmali M A., Becker L E., Smith C R. The histopathology of the hemolytic uremic syndrome associated with verocytotoxin-producing Escherichia coli infections. Hum Pathol 1988 19 (9) 1102-1108
88. Michael M, Elliott E J., Ridley G F., Hodson E M., Craig J C. Interventions for haemolytic uraemic syndrome and thrombotic thrombocytopenic purpura. Cochrane Database Syst Rev 2009 (1) CD003595
89. Michael M, Elliott E J., Craig J C., Ridley G, Hodson E M. Interventions for hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: a systematic review of randomized controlled trials. Am J Kidney Dis 2009 53 (2) 259-272
90. Vitacco M, Sanchez Avalos J, Gianantonio C A. Heparin therapy in the hemolytic-uremic syndrome. J Pediatr 1973 83 (2) 271-275
91. Loirat C, Beaufils F, Sonsino E et al. Treatment of childhood hemolytic-uremic syndrome with urokinase. Cooperative controlled trial [in French]. Arch Fr Pediatr 1984 41 (1) 15-19
92. Van Damme-Lombaerts R, Proesmans W, Van Damme B et al. Heparin plus dipyridamole in childhood hemolytic-uremic syndrome: a prospective, randomized study. J Pediatr 1988 113 (5) 913-918
93. Loirat C, Sonsino E, Hinglais N, Jais J P., Landais P, Fermanian J, The French Society of Paediatric Nephrology. Treatment of the childhood haemolytic uraemic syndrome with plasma. A multicentre randomized controlled trial. Pediatr Nephrol 1988 2 (3) 279-285
94. Rizzoni G, Claris-Appiani A, Edefonti A et al. Plasma infusion for hemolytic-uremic syndrome in children: results of a multicenter controlled trial. J Pediatr 1988 112 (2) 284-290
95. Perez N, Spizzirri F, Rahman R, Suarez A, Larrubia C, Lasarte P. Steroids in the hemolytic uremic syndrome. Pediatr Nephrol 1998 12 (2) 101-104
96. Trachtman H, Cnaan A, Christen E et al, Investigators of the HUS-SYNSORB Pk Multicenter Clinical Trial. Effect of an oral Shiga toxin-binding agent on diarrhea-associated hemolytic uremic syndrome in children: a randomized controlled trial. JAMA 2003 290 (10) 1337-1344
97. Siegler R L., Pysher T J., Tesh V L., Denkers N D., Taylor F B. Prophylactic heparinization is ineffective in a primate model of hemolytic uremic syndrome. Pediatr Nephrol 2002 17 (12) 1053-1058
98. Landau D, Shalev H, Levy-Finer G, Polonsky A, Segev Y, Katchko L. Familial hemolytic uremic syndrome associated with complement factor H deficiency. J Pediatr 2001 138 (3) 412-417
99. Licht C, Weyersberg A, Heinen S et al. Successful plasma therapy for atypical hemolytic uremic syndrome caused by factor H deficiency owing to a novel mutation in the complement cofactor protein domain 15. Am J Kidney Dis 2005 45 (2) 415-421
100. Lapeyraque A L., Wagner E, Phan V et al. Efficacy of plasma therapy in atypical hemolytic uremic syndrome with complement factor H mutations. Pediatr Nephrol 2008 23 (8) 1363-1366
101. Ariceta G, Besbas N, Johnson S et al, European Paediatric Study Group for HUS. Guideline for the investigation and initial therapy of diarrhea-negative hemolytic uremic syndrome. Pediatr Nephrol 2009 24 (4) 687-696
102. De S, Waters A M., Segal A O., Trautmann A, Harvey E A., Licht C. Severe atypical HUS caused by CFH S1191L-case presentation and review of treatment options. Pediatr Nephrol 2010 25 (1) 97-104
103. Armstrong G D., Rowe P C., Goodyer P et al. A phase I study of chemically synthesized verotoxin (Shiga-like toxin) Pk-trisaccharide receptors attached to chromosorb for preventing hemolytic-uremic syndrome. J Infect Dis 1995 171 (4) 1042-1045
104. Nishikawa K, Matsuoka K, Watanabe M et al. Identification of the optimal structure required for a Shiga toxin neutralizer with oriented carbohydrates to function in the circulation. J Infect Dis 2005 191 (12) 2097-2105
105. Bitzan M, Ludwig K, Klemt M, König H, Büren J, Müller-Wiefel D E. The role of Escherichia coli O 157 infections in the classical (enteropathic) haemolytic uraemic syndrome: results of a Central European, multicentre study. Epidemiol Infect 1993 110 (2) 183-196
106. Ahmed A, Li J, Shiloach Y, Robbins J B., Szu S C. Safety and immunogenicity of Escherichia coli O157 O-specific polysaccharide conjugate vaccine in 25-year-old children. J Infect Dis 2006 193 (4) 515-521
107. Wen S X., Teel L D., Judge N A., O'Brien A D. A plant-based oral vaccine to protect against systemic intoxication by Shiga toxin type 2. Proc Natl Acad Sci U S A 2006 103 (18) 7082-7087
108. Gao X, Cai K, Shi J et al. Immunogenicity of a novel Stx2B-Stx1B fusion protein in a mice model of enterohemorrhagic Escherichia coli O157:H7 infection. Vaccine 2009 27 (14) 2070-2076
109. Gu J, Liu Y, Yu S et al. Enterohemorrhagic Escherichia coli trivalent recombinant vaccine containing EspA, intimin and Stx2 induces strong humoral immune response and confers protection in mice. Microbes Infect 2009 11 (10-11) 835-841
110. Bentancor L V., Bilen M, Brando R J. et al. A DNA vaccine encoding the enterohemorrhagic Escherichia coli Shiga-like toxin 2 A2 and B subunits confers protective immunity to Shiga toxin challenge in the murine model. Clin Vaccine Immunol 2009 16 (5) 712-718
111. Kitov P I., Sadowska J M., Mulvey G et al. Shiga-like toxins are neutralized by tailored multivalent carbohydrate ligands. Nature 2000 403 (6770) 669-672
112. Mulvey G L., Marcato P, Kitov P I., Sadowska J, Bundle D R., Armstrong G D. Assessment in mice of the therapeutic potential of tailored, multivalent Shiga toxin carbohydrate ligands. J Infect Dis 2003 187 (4) 640-649
113. Watanabe M, Matsuoka K, Kita E et al. Oral therapeutic agents with highly clustered globotriose for treatment of Shiga toxigenic Escherichia coli infections. J Infect Dis 2004 189 (3) 360-368
114. Migita M, Mizukami E, Gunji Y P. Flexibility in starfish behavior by multi-layered mechanism of self-organization. Biosystems 2005 82 (2) 107-115
115. Yamada Y, Miura Y, Sakaki A, Yoshida T, Kobayashi K. Design of multifunctional peptides expressing both antimicrobial activity and shiga toxin neutralization activity. Bioorg Med Chem 2006 14 (1) 77-82
116. Bitzan M. Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int Suppl 2009 (112) S62-S66
117. Cavagnaro F, Vogel A, Ronco R, Rodrguez J I. Continuous hemofiltration in patients with abdominal complications of hemolytic uremic syndrome [in Spanish]. Rev Med Chil 2002 130 (7) 768-772
118. Kavanagh D, Richards A, Atkinson J. Complement regulatory genes and hemolytic uremic syndromes. Annu Rev Med 2008 59 293-309
119. Lhotta K, Janecke A R., Scheiring J et al. A large family with a gain-of-function mutation of complement C3 predisposing to atypical hemolytic uremic syndrome, microhematuria, hypertension and chronic renal failure. Clin J Am Soc Nephrol 2009 4 (8) 1356-1362
120. Chatelet V, Frémeaux-Bacchi V, Lobbedez T, Ficheux M, Hurault de Ligny B. Safety and long-term efficacy of eculizumab in a renal transplant patient with recurrent atypical hemolytic-uremic syndrome. Am J Transplant 2009 9 (11) 2644-2645
121. Nürnberger J, Philipp T, Witzke O et al. Eculizumab for atypical hemolytic-uremic syndrome. N Engl J Med 2009 360 (5) 542-544
122. Banda N K., Levitt B, Glogowska M J. et al. Targeted inhibition of the complement alternative pathway with complement receptor 2 and factor H attenuates collagen antibody-induced arthritis in mice. J Immunol 2009 183 (9) 5928-5937
123. Nguyen T C., Stegmayr B, Busund R, Bunchman T E., Carcillo J A. Plasma therapies in thrombotic syndromes. Int J Artif Organs 2005 28 (5) 459-465
124. Iijima K, Kamioka I, Nozu K. Management of diarrhea-associated hemolytic uremic syndrome in children. Clin Exp Nephrol 2008 12 (1) 16-19
125. Tarr P I. Shiga toxin-associated hemolytic uremic syndrome and thrombotic thrombocytopenic purpura: distinct mechanisms of pathogenesis. Kidney Int Suppl 2009 (112) S29-S32
126. Dundas S, Murphy J, Soutar R L., Jones G A., Hutchinson S J., Todd W T. Effectiveness of therapeutic plasma exchange in the 1996 Lanarkshire Escherichia coli O157:H7 outbreak. Lancet 1999 354 (9187) 1327-1330
127. Shaz B H., Linenberger M L., Bandarenko N et al. Category IV indications for therapeutic apheresis: ASFA fourth special issue. J Clin Apher 2007 22 (3) 176-180
128. Garg A X., Suri R S., Barrowman N et al. Long-term renal prognosis of diarrhea-associated hemolytic uremic syndrome: a systematic review, meta-analysis, and meta-regression. JAMA 2003 290 (10) 1360-1370
129. Edey M M., Mead P A., Saunders R E. et al. Association of a factor H mutation with hemolytic uremic syndrome following a diarrheal illness. Am J Kidney Dis 2008 51 (3) 487-490
130. Karpac C A., Li X, Terrell D R. et al. Sporadic bloody diarrhoea-associated thrombotic thrombocytopenic purpura-haemolytic uraemic syndrome: an adult and paediatric comparison. Br J Haematol 2008 141 (5) 696-707
131. Orth D, Khan A B., Naim A et al. Shiga toxin activates complement and binds factor H: evidence for an active role of complement in hemolytic uremic syndrome. J Immunol 2009 182 (10) 6394-6400
132. Thurman J M., Marians R, Emlen W et al. Alternative pathway of complement in children with diarrhea-associated hemolytic uremic syndrome. Clin J Am Soc Nephrol 2009 4 (12) 1920-1924
133. Strockbine N A., Marques L R., Holmes R K., O'Brien A D. Characterization of monoclonal antibodies against Shiga-like toxin from Escherichia coli. Infect Immun 1985 50 (3) 695-700
134. Perera L P., Marques L R., O'Brien A D. Isolation and characterization of monoclonal antibodies to Shiga-like toxin II of enterohemorrhagic Escherichia coli and use of the monoclonal antibodies in a colony enzyme-linked immunosorbent assay. J Clin Microbiol 1988 26 (10) 2127-2131
135. Dowling T C., Chavaillaz P A., Young D G. et al. Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c alpha Stx2 administered intravenously to healthy adult volunteers. Antimicrob Agents Chemother 2005 49 (5) 1808-1812
136. Nakao H, Kiyokawa N, Fujimoto J, Yamasaki S, Takeda T. Monoclonal antibody to Shiga toxin 2 which blocks receptor binding and neutralizes cytotoxicity. Infect Immun 1999 67 (11) 5717-5722
137. Nakao H, Kataoka C, Kiyokawa N, Fujimoto J, Yamasaki S, Takeda T. Monoclonal antibody to shiga toxin 1, which blocks receptor binding and neutralizes cytotoxicity. Microbiol Immunol 2002 46 (11) 777-780 (Pubitemid 35428955)
138. Kimura T, Co M S., Vasquez M et al. Development of humanized monoclonal antibody TMA-15 which neutralizes Shiga toxin 2. Hybrid Hybridomics 2002 21 (3) 161-168
139. Yamagami S, Motoki M, Kimura T et al. Efficacy of postinfection treatment with anti-Shiga toxin (Stx) 2 humanized monoclonal antibody TMA-15 in mice lethally challenged with Stx-producing Escherichia coli. J Infect Dis 2001 184 (6) 738-742
140. Teijin America, Inc. Strategy, issues, and alternative approaches in development of a treatment for HUS prevention. Joint meeting of the Anti-Infective Drugs Advisory Committee and the Pediatric Advisory Committee of the US Food and Drug Administration (FDA). Available at: www.fda.gov/ohrms/ dockets/ac/07/slides/2007-4286s1-08-teijin-brookman-cato-peterson-files/frame. htm Accessed July 8, 2010
141. López E L., Contrini M M., Glatstein E et al. Safety and pharmacokinetics of urtoxazumab, a humanized monoclonal antibody against Shiga-like toxin 2 in healthy adults and pediatric patients infected with Shiga-like toxin-producing Escherichia coli. Antimicrob Agents Chemother 2010 54 239-243
142. Mukherjee J, Chios K, Fishwild D et al. Human Stx2-specific monoclonal antibodies prevent systemic complications of Escherichia coli O157:H7 infection. Infect Immun 2002 70 (2) 612-619
143. Akiyoshi D E., Rich C M., O'Sullivan-Murphy S et al. Characterization of a human monoclonal antibody against Shiga toxin 2 expressed in Chinese hamster ovary cells. Infect Immun 2005 73 (7) 4054-4061
144. Sheoran A S., Chapman S, Singh P, Donohue-Rolfe A, Tzipori S. Stx2-specific human monoclonal antibodies protect mice against lethal infection with Escherichia coli expressing Stx2 variants. Infect Immun 2003 71 (6) 3125-3130
145. Tzipori S, Sheoran A, Akiyoshi D, Donohue-Rolfe A, Trachtman H. Antibody therapy in the management of Shiga toxin-induced hemolytic uremic syndrome. Clin Microbiol Rev 2004 17 (4) 926-941
146. Inoue K, Itoh K, Nakao H, Takeda T, Suzuki T. Characterization of a Shiga toxin 1-neutralizing recombinant Fab fragment isolated by phage display system. Tohoku J Exp Med 2004 203 (4) 295-303
147. Ma Y, Mao X, Li J et al. Engineering an anti-Stx2 antibody to control severe infections of EHEC O157:H7. Immunol Lett 2008 121 (2) 110-115
148. Liu X Y., Pop L M., Vitetta E S. Engineering therapeutic monoclonal antibodies. Immunol Rev 2008 222 9-27
149. Smith M J., Melton-Celsa A R., Sinclair J F., Carvalho H M., Robinson C M., O'Brien A D. Monoclonal antibody 11E10, which neutralizes shiga toxin type 2 (Stx2), recognizes three regions on the Stx2 A subunit, blocks the enzymatic action of the toxin in vitro, and alters the overall cellular distribution of the toxin. Infect Immun 2009 77 (7) 2730-2740
150. Smith M J., Carvalho H M., Melton-Celsa A R., O'Brien A D. The 13C4 monoclonal antibody that neutralizes Shiga toxin Type 1 (Stx1) recognizes three regions on the Stx1 B subunit and prevents Stx1 from binding to its eukaryotic receptor globotriaosylceramide. Infect Immun 2006 74 (12) 6992-6998
151. Karmali M A. Prospects for preventing serious systemic toxemic complications of Shiga toxin-producing Escherichia coli infections using Shiga toxin receptor analogues. J Infect Dis 2004 189 (3) 355-359